| CAS No.: | 117928-94-6 |
|---|---|
| Formula: | C18h31n5o6 |
| EINECS: | N/a |
| Type: | Peptides Powder |
| Appearance: | Powder |
| Quality: | Top Quality |
| Samples: |
|---|
| Customization: |
|---|
Suppliers with verified business licenses
Audited Supplier 
| Product name | Glyx-13 |
| Appearance | White powder |
| Purity | 99% |
| Storage | Keep in a cool, dry, dark location in a tightly sealed container or cylinder. |
| Shelf Life | 24 Months |
Description
Rapastinel is a novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant
major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide
(Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site at
the glycine site of the NMDA receptor complex (Emax ≈ 25%).
The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability
to both inhibit and enhance NMDA receptor-mediated signal transduction.
Application&Function
GLYX-13 is a long lasting and rapid acting antidepressant. Investigational drug for the treatment of depressive disoder.
GLYX-13 trifluoroacetate has been used as an activator of NMDA (N-methyl-D-aspartate) receptor.
Suppliers with verified business licenses
Audited Supplier 
){kind=link}
){kind=link}